Pathways mediating resistance to vascular endothelial growth factor-targeted therapy

Clinical Cancer Research

Volumn 14, Issue 20, 2008, Pages 6371-6375

  Ellis, Leem ^a,c   Hicklin, Daniel J ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CD11B ANTIGEN; FIBROBLAST GROWTH FACTOR; MONOCLONAL ANTIBODY VASCULOTROPIN RECEPTOR 2; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; ANGIOGENESIS INHIBITOR; PROTEIN KINASE INHIBITOR; VASCULOTROPIN A;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; COLORECTAL CANCER; DRUG TARGETING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; TREATMENT RESPONSE; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); SIGNAL TRANSDUCTION;

ANGIOGENESIS INHIBITORS; ANIMALS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 58149190795     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-5287     Document Type: Review

References (41)

1. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-9.
2. Sandler A,Gray R,Perry MC,et al. Paclitaxel-carbo-platin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
3. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokinein tumoran-giogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368-80.
4. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angio-genesis. J Clin Oncol 2005;23:1011 -27.
5. Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 2006;12:5018-22.
6. Sato Y, Kanno S, Oda N, et al. Properties of two VEGF receptors, Flt-1 and KDR, in signal transduction. Ann N YAcad Sci 2000;902:201 -5; discussion 5 -7.
7. Rafii S, Lyden D, Benezra R, Hattori K, Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2002;2:826-35.
8. Purhonen S, Palm J, Rossi D, et al. Bone marrow-derived circulating endothelial precursors do not contributeto vascular endothelium and are not needed for tumor growth. Proc Natl Acad Sci U S A 2008;105:6620-5.
9. Laakkonen P, Waltari M, HolopainenT, et al. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res 2007;67:593-9.
10. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 2002;1:219-27.
11. Kukk E, Lymboussaki A, Taira S, et al.VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development1996;122:3829-37.
12. Bielenberg DR, Klagsbrun M. Targeting endothelial and tumor cells with semaphorins. Cancer Metastasis Rev 2007;26:421-31.
13. Ellis LM. The role ofneuropilins in cancer. Mol Cancer Ther 2006;5:1099-107.
14. Klagsbrun M, Takashima S, Mamluk R. The role of neuropilin in vascular and tumor biology. Adv Exp Med Biol 2002;515:33-48.
15. Mamluk R, Gechtman Z, Kutcher ME, Gasiunas N, Gallagher J, Klagsbrun M. Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain. J Biol Chem 2002;277:24818-25.
16. Soker S, Miao HQ, Nomi M,Takashima S, Klagsbrun M. VEGF 165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J Cell Biochem 2002;85:357-68.
17. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998;92:735-45.
18. Pan Q, ChantheryY, Liang WC, et al. Blocking neuropilin-1function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 2007;11:53-67.
19. Karaman MW, Herrgard S,Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Bio-technol 2008;26:127-32.
20. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309.
21. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95.
22. Yan M, Plowman GD Delta-like 4/notch signaling and its therapeutic implications. Clin Cancer Res 2007;13:7243-6.
23. Noguera-Troise I, Daly C, Papadopoulos NJ, et al. Blockade of Dll4 inhibits tumour growth bypromoting non-productive angiogenesis. Nature 2006;444:1032-7.
24. Ridgway J, Zhang G, Wu Y, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating an-giogenesis. Nature 2006;444:1083-7.
25. Ebos JML, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA2007;104:17069-74.
26. Fischer C, Jonckx B, Mazzone M, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007;131:463-75.
27. D'Amore PA.Vascular endothelial cell growth factor-a: not just for endothelial cells anymore. Am J Pathol 2007;171:14-8.
28. Reinmuth N, Liu W, Jung YD, et al. Induction of VEGF in perivascularcells defines a potential paracrine mechanism for endothelial cell survival. FASEB J 2001;15:1239-41.
29. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999;103:159-65.
30. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vas-cularnormalization byVEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix met alloproteinases. Cancer Cell 2004;6:553-63.
31. Shaheen RM, Tseng WW, Davis DW, et al. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in micebearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res 2001;61:1464-8.
32. PietrasK, Pahler J, Bergers G, Hanahan D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med 2008;5:e19.
33. Shojaei F, Wu X, Malik AK, et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1 + myeloid cells. Nat Biotechnol 2007;25:911-20.
34. Shojaei F, Singh M, Thompson JD, Ferrara N. Roleof Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc Natl Acad Sci U S A 2008;105:2640-5.
35. Shojaei F,Wu X, Zhong C, et al. Bv8 regulates mye-loid-cell-dependent tumour angiogenesis. Nature 2007;450:825-31.
36. Mollay C,Wechselberger C, Mignogna G, et al. Bv8, a small protein from frog skin and its homologue from snake venom induce hyperalgesia in rats. Eur J Pharmacol 1999;374:189-96.
37. GrotheyA, Surgrue M, Purdie D, Dong W, Sargent DJ, Kozloff M. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRITE). J Clin Oncol. In press 2008.
38. Escudier B, EisenT, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
39. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bev-acizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-44.
40. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon a in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
41. Ellis L, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8:579-91.